Clinical trial
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid…
NCT00049023 · O'Dorisio, M S, Other · Completed
Key facts
| NCT number | NCT00049023 |
|---|---|
| Title | Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors |
| Official title | A Phase I, Open Label, Maximum Tolerated Dose-Finding Study to Evaluate the Safety and Tolerability of 90Y-DOTA-tyr3-Octreotide Administered by Intravenous Infusion to Children With Refractory Somatostatin-Receptor Positive Tumors |
| Lead sponsor | O'Dorisio, M S, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neuroblastoma, Pheochromocytoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific |
| Intervention type | Radiation |
| Interventions | 90Y-DOTA-tyr3-OCTREOTIDE |
| Enrollment | 27 |
| Start date | Jan 1, 2002 |
| Primary completion | Aug 1, 2011 |
| Completion | Aug 1, 2011 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 21, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: